BCL2L1 and leukemia: Treatment of K562 leukemia cells with IL-6 resulted in a reduction in the Bcl-xL/Bcl-xS ratio; nucleotides 1–176 of the downstream intron were found to be required for the IL-6 effect (Li et al., 2004).